MAIA Biotechnology, Inc. MAIA
MAIA Biotechnology, Inc. (NYSE: MAIA) is an oncology drug developer. Its lead program, ateganosine (THIO), is in Phase 3 for third-line non-small cell lung cancer (NSCLC), CPI- and chemotherapy-resistant. Its next catalyst on record is ateganosine (THIO-101): Filing for accelerated approval in advanced NSCLC (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ateganosine (THIO-101) — Filing for accelerated approval in advanced NSCLC (2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ateganosine - THIO-104 (pivotal, with checkpoint inhibitor) | 3L NSCLC | small molecule | Phase 3 |
| ateganosine - THIO-101 (with cemiplimab) | advanced NSCLC (Part C / 3L expansion) | small molecule | Phase 2 |
| ateganosine + tislelizumab - THIO-102 (HCC, CRC, SCLC) | hepatocellular carcinoma; colorectal cancer; small cell lung cancer | small molecule | Pre-clinical |
| second-generation telomere-targeting molecules | — | small molecule | Pre-clinical |
Recent results and decisions
- Dec 11, 2025started First patient dosed in the THIO-104 Phase 3 pivotal trial of ateganosine sequenced with a checkpoint inhibitor vs chemotherapy in 3L NSCLC (up to 300 patients, overall survival primary endpoint).
today announced that the first patient has been dosed in the Company’s THIO-104 Phase 3 pivotal trial evaluating the efficacy of ateganosine administered in sequence with a checkpoint inhibitor (CPI) as a third-line treatment for advanced non-small cell lung cancer (NSCLC).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.